Cargando…
“A sense of the bigger picture:” A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use
OBJECTIVES: People with bipolar disorder (BD) spend more time depressed than manic/hypomanic, and depression is associated with greater impairments in psychosocial functioning and quality of life than mania/hypomania. Emerging evidence suggests psilocybin, the psychoactive compound in “magic mushroo...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749989/ https://www.ncbi.nlm.nih.gov/pubmed/36516137 http://dx.doi.org/10.1371/journal.pone.0279073 |
_version_ | 1784850150222462976 |
---|---|
author | DellaCrosse, Meghan Pleet, Mollie Morton, Emma Ashtari, Amir Sakai, Kimberly Woolley, Josh Michalak, Erin |
author_facet | DellaCrosse, Meghan Pleet, Mollie Morton, Emma Ashtari, Amir Sakai, Kimberly Woolley, Josh Michalak, Erin |
author_sort | DellaCrosse, Meghan |
collection | PubMed |
description | OBJECTIVES: People with bipolar disorder (BD) spend more time depressed than manic/hypomanic, and depression is associated with greater impairments in psychosocial functioning and quality of life than mania/hypomania. Emerging evidence suggests psilocybin, the psychoactive compound in “magic mushrooms,” is a promising treatment for unipolar depression. Clinical trials of psilocybin therapy have excluded people with BD as a precaution against possible adverse effects (e.g., mania). Our study centered the experiences of adults living with BD who consumed psilocybin-containing mushrooms, and aimed to (1) understand its subjective impacts on BD symptoms, (2) deepen understanding of Phase I survey results, and (3) elucidate specific contextual factors associated with adverse reactions in naturalistic settings. METHODS: Following an international survey (Phase I), follow-up interviews were conducted with 15 respondents (Phase II) to further understand psilocybin use among adults with BD. As part of a larger mixed-methods explanatory sequential design study, reflexive thematic analysis was used to elaborate findings. RESULTS: Three major themes containing sub-themes were developed. (1) Mental Health Improvements: (1.1) decreased impact and severity of depression, (1.2) increased emotion processing, (1.3) development of new perspectives, and (1.4) greater relaxation and sleep. (2) Undesired Mental Health Impacts: (2.1) changes in sleep, (2.2) increased mania severity, (2.3) hospitalization, and (2.4) distressing sensory experiences. (3) Salient Contextual Factors for psilocybin use included: (3.1) poly-substance use and psilocybin dose, (3.2) solo versus social experiences, and (3.3) pre-psilocybin sleep deprivation. CONCLUSION: Our findings demonstrate both benefits and risks of psilocybin use in this population. Carefully designed clinical trials focused on safety and preliminary efficacy are warranted. |
format | Online Article Text |
id | pubmed-9749989 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-97499892022-12-15 “A sense of the bigger picture:” A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use DellaCrosse, Meghan Pleet, Mollie Morton, Emma Ashtari, Amir Sakai, Kimberly Woolley, Josh Michalak, Erin PLoS One Research Article OBJECTIVES: People with bipolar disorder (BD) spend more time depressed than manic/hypomanic, and depression is associated with greater impairments in psychosocial functioning and quality of life than mania/hypomania. Emerging evidence suggests psilocybin, the psychoactive compound in “magic mushrooms,” is a promising treatment for unipolar depression. Clinical trials of psilocybin therapy have excluded people with BD as a precaution against possible adverse effects (e.g., mania). Our study centered the experiences of adults living with BD who consumed psilocybin-containing mushrooms, and aimed to (1) understand its subjective impacts on BD symptoms, (2) deepen understanding of Phase I survey results, and (3) elucidate specific contextual factors associated with adverse reactions in naturalistic settings. METHODS: Following an international survey (Phase I), follow-up interviews were conducted with 15 respondents (Phase II) to further understand psilocybin use among adults with BD. As part of a larger mixed-methods explanatory sequential design study, reflexive thematic analysis was used to elaborate findings. RESULTS: Three major themes containing sub-themes were developed. (1) Mental Health Improvements: (1.1) decreased impact and severity of depression, (1.2) increased emotion processing, (1.3) development of new perspectives, and (1.4) greater relaxation and sleep. (2) Undesired Mental Health Impacts: (2.1) changes in sleep, (2.2) increased mania severity, (2.3) hospitalization, and (2.4) distressing sensory experiences. (3) Salient Contextual Factors for psilocybin use included: (3.1) poly-substance use and psilocybin dose, (3.2) solo versus social experiences, and (3.3) pre-psilocybin sleep deprivation. CONCLUSION: Our findings demonstrate both benefits and risks of psilocybin use in this population. Carefully designed clinical trials focused on safety and preliminary efficacy are warranted. Public Library of Science 2022-12-14 /pmc/articles/PMC9749989/ /pubmed/36516137 http://dx.doi.org/10.1371/journal.pone.0279073 Text en https://creativecommons.org/publicdomain/zero/1.0/This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication. |
spellingShingle | Research Article DellaCrosse, Meghan Pleet, Mollie Morton, Emma Ashtari, Amir Sakai, Kimberly Woolley, Josh Michalak, Erin “A sense of the bigger picture:” A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use |
title | “A sense of the bigger picture:” A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use |
title_full | “A sense of the bigger picture:” A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use |
title_fullStr | “A sense of the bigger picture:” A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use |
title_full_unstemmed | “A sense of the bigger picture:” A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use |
title_short | “A sense of the bigger picture:” A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use |
title_sort | “a sense of the bigger picture:” a qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749989/ https://www.ncbi.nlm.nih.gov/pubmed/36516137 http://dx.doi.org/10.1371/journal.pone.0279073 |
work_keys_str_mv | AT dellacrossemeghan asenseofthebiggerpictureaqualitativeanalysisoffollowupinterviewswithpeoplewithbipolardisorderwhoselfreportedpsilocybinuse AT pleetmollie asenseofthebiggerpictureaqualitativeanalysisoffollowupinterviewswithpeoplewithbipolardisorderwhoselfreportedpsilocybinuse AT mortonemma asenseofthebiggerpictureaqualitativeanalysisoffollowupinterviewswithpeoplewithbipolardisorderwhoselfreportedpsilocybinuse AT ashtariamir asenseofthebiggerpictureaqualitativeanalysisoffollowupinterviewswithpeoplewithbipolardisorderwhoselfreportedpsilocybinuse AT sakaikimberly asenseofthebiggerpictureaqualitativeanalysisoffollowupinterviewswithpeoplewithbipolardisorderwhoselfreportedpsilocybinuse AT woolleyjosh asenseofthebiggerpictureaqualitativeanalysisoffollowupinterviewswithpeoplewithbipolardisorderwhoselfreportedpsilocybinuse AT michalakerin asenseofthebiggerpictureaqualitativeanalysisoffollowupinterviewswithpeoplewithbipolardisorderwhoselfreportedpsilocybinuse |